Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL12180048 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL14373308 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL4896486 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL7004654 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223196 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL13123063 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL23743979 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Epiestriol SCHEMBL221084 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223226 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL8941750 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| US-6901278-B1 | Diagnosis; genotype breast estrogen receptors; forming therapy ; calibrating hormone replacement therapy | THE BRAIN HEALTH PROJECT LLC | 2005-05-31 | — | — | US | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| US-6086915-A | HEATING THE SOLUBILIZING EMULSIFIER, ADDING SOLVENT AND ONE OR MORE PHOSPHOLIPID SURFACTANTS, DISSOLVING IN THIS SOLUTION ONE OR MORE HYDROPHOBIC PHYTOCHEMICALS, ADDING ENCAPSULATORS, FORMING MICROEMULSION, SPRAY DRYING THE SOLUTION | BIORESPONSE L.L.C. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0566566-B1 | COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS | APPLIED MED RES LTD (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0566566-A1 | COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS. | APPLIED MED RES LTD (US) | 1993-10-27 | — | — | EP | disclosed |
| WO-1992011855-A1 | COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS | APPLIED MEDICAL RESEARCH, LTD. (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | ESR1 5/4885ESR2 1/4885LMNA 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.